Professor | Yongshun Chen | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Yongshun Chen
Contact Information	yongshun2007@163.com
Language ability	English, Chinese
Province	Hubei

Upload Avatar (500 x 500)

Name

Yongshun Chen

Contact Information

yongshun2007@163.com

Language ability

English, Chinese

Province

Hubei

University/Lab Affiliation and Title	Wuhan University
Faculty	Medical School
Academic Background & Achievements	1995.09-2000.06 Bachelor of Clinical Medicine, Henan Medical University 2003.09-2006.06 Master of Pathology and Pathophysiology, Zhengzhou University 2007.09-2010.06 PhD in Oncology, West China School of Clinical Medicine, Sichuan University Hosted 8 national and provincial projects, published over 50 papers
Work Experience	2000.08-2007.08 Resident and Attending Physician, Oncology, Zhengzhou People's Hospital 2010.08-2016.08 Associate Chief Physician, Zhengzhou University Affiliated Oncology Hospital 2013.07-2014.05 Postdoctoral Researcher, Peter MacCallum Cancer Center, Australia 2016.09-present Professor and Chief Physician, Oncology Center, Renmin Hospital of Wuhan University
Awards	2015 Second Prize for Medical Technology Introduction for 'Cetuximab combined with concurrent chemoradiotherapy for locally advanced esophageal cancer' 2020 Second Prize for Scientific and Technological Progress in Hubei Province for 'Innovation and application of targeted and intelligent radiotherapy quality control system'

University/Lab Affiliation and Title

Wuhan University

Faculty

Medical School

Academic Background & Achievements

1995.09-2000.06 Bachelor of Clinical Medicine, Henan Medical University
2003.09-2006.06 Master of Pathology and Pathophysiology, Zhengzhou University
2007.09-2010.06 PhD in Oncology, West China School of Clinical Medicine, Sichuan University
Hosted 8 national and provincial projects, published over 50 papers

Work Experience

2000.08-2007.08 Resident and Attending Physician, Oncology, Zhengzhou People's Hospital
2010.08-2016.08 Associate Chief Physician, Zhengzhou University Affiliated Oncology Hospital
2013.07-2014.05 Postdoctoral Researcher, Peter MacCallum Cancer Center, Australia
2016.09-present Professor and Chief Physician, Oncology Center, Renmin Hospital of Wuhan University

Awards

2015 Second Prize for Medical Technology Introduction for 'Cetuximab combined with concurrent chemoradiotherapy for locally advanced esophageal cancer'
2020 Second Prize for Scientific and Technological Progress in Hubei Province for 'Innovation and application of targeted and intelligent radiotherapy quality control system'

Areas of Focus	Integrative therapy of digestive oncology Radiosensitization and cancer therapy
Publications	With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous carcinoma of the esophagus: a propensity score-matched analysis., Yongshun Chen, 2018 Enhancing the Photodynamic Therapy Efficacy of Black Phosphorus Nanosheets by Covalently Grafting Fullerene C60., Yongshun Chen, 2020 Buffer wards for the control of COVID-19 transmission in hospitals., Yongshun Chen, 2020 Dysfunction of apoptosis and autophagy correlates with local recurrence in esophageal squamous cell carcinoma after definitive chemoradiation., Yongshun Chen, 2021 Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses., Yongshun Chen, 2021 Preoperative chemotherapy for limited-stage small cell carcinoma of the esophagus., Yongshun Chen, 2022 Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy., Yongshun Chen, 2022 Evaluation of Concurrent Chemoradiotherapy in Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma., Yongshun Chen, 2022 Circ_0011385 knockdown inhibits cell proliferation, migration and invasion, whereas promotes cell apoptosis by regulating miR-330-3p/MYO6 axis in colorectal cancer., Yongshun Chen, 2023 Aspirin induces immunogenic cell death and enhances cancer immunotherapy in colorectal cancer., Yongshun Chen, 2023 Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial., Yongshun Chen, 2023 Efficacy of endoscopic therapy for T1b esophageal cancer and construction of prognosis prediction model: a retrospective cohort study., Yongshun Chen, 2023

Areas of Focus

Integrative therapy of digestive oncology
Radiosensitization and cancer therapy

Publications

With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous carcinoma of the esophagus: a propensity score-matched analysis., Yongshun Chen, 2018
Enhancing the Photodynamic Therapy Efficacy of Black Phosphorus Nanosheets by Covalently Grafting Fullerene C60., Yongshun Chen, 2020
Buffer wards for the control of COVID-19 transmission in hospitals., Yongshun Chen, 2020
Dysfunction of apoptosis and autophagy correlates with local recurrence in esophageal squamous cell carcinoma after definitive chemoradiation., Yongshun Chen, 2021
Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses., Yongshun Chen, 2021
Preoperative chemotherapy for limited-stage small cell carcinoma of the esophagus., Yongshun Chen, 2022
Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy., Yongshun Chen, 2022
Evaluation of Concurrent Chemoradiotherapy in Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma., Yongshun Chen, 2022
Circ_0011385 knockdown inhibits cell proliferation, migration and invasion, whereas promotes cell apoptosis by regulating miR-330-3p/MYO6 axis in colorectal cancer., Yongshun Chen, 2023
Aspirin induces immunogenic cell death and enhances cancer immunotherapy in colorectal cancer., Yongshun Chen, 2023
Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial., Yongshun Chen, 2023
Efficacy of endoscopic therapy for T1b esophageal cancer and construction of prognosis prediction model: a retrospective cohort study., Yongshun Chen, 2023

Digestive Oncology Integrative Therapy Radiosensitization Cancer Therapy Clinical Research Targeted Therapy Radiation Therapy Oncology Treatment Protocols Clinical Outcomes

Lin Congyao - Wuhan University

Hai-Xia Ding - Wuhan University

Yi Zongbi - Wuhan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us